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Abstract
Bupivacaine, a local anesthetic and cationic amphiphile, forms stable liposomal-like structures upon direct mixing with
plasmid DNA in aqueous solutions. These structures are on the order of 50^70 nm as determined by scanning electron
microscopy, and are homogeneous populations as analyzed by density gradient centrifugation. The DNA within these
structures is protected from nuclease degradation and UV-induced damage in vitro. Bupivacaine:DNA complexes have a
negative zeta potential (surface charge), homogeneous nature, and an ability to rapidly assemble in aqueous solutions.
Bupivacaine:DNA complexes, as well as similar complexes of DNA with other local anesthetics, have the potential to be a
novel class of DNA delivery agents for gene therapy and DNA vaccines. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
DNA immunization and gene therapy using non-
viral vectors require e⁄cient methods for delivery of
plasmid DNA to target cells in vivo. Complexes of
plasmid DNA and synthetic cationic lipids, such as
DOTMA and DOTAP, have been successful in en-
hancing transfection, in cell culture. However, in
general, these cationic lipid:DNA complexes do not
result in increased muscle cell transfection after in
vivo intramuscular injection, nor immune responses
against antigens encoded by the DNA, when com-
pared to naked DNA [1].
Although naked DNA can transfect muscle cells in
vivo, pretreatment of muscle with the local anesthetic
bupivacaine several days prior to injection of DNA,
results in increased DNA uptake, as evidenced by
increased DNA expression at the injection site [2,3].
Increased expression of DNA is also associated with
increased immune responses to antigens encoded by
the injected DNA [4] (unpublished data Higgins,
Shro¡). Increase in muscle transfection by pretreat-
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ment with bupivacaine is thought to be due to the
myogenic activity of bupivacaine. Treatment of
muscle with bupivacaine causes muscle ¢ber degen-
eration, and subsequent recruitment of myoblasts
into muscle regeneration [2]. Dividing myoblasts
are postulated to be more likely to be transfected
with DNA than the non-dividing, di¡erentiated
muscle cells, and are presumably responsible for the
observed increase in muscle transfection. In addition,
the recruitment of in£ammatory cells to the site of
bupivacaine injection [2,3,5,6] may allow for trans-
fection of immune cells, as well. Due to the temporal
nature of muscle cell degeneration and regeneration,
the window of opportunity to transfect regenerating
muscle ¢bers is 1 to 7 days post-bupivacaine treat-
ment.
We have shown that mixtures of DNA and bupi-
vacaine delivered simultaneously also result in in-
creased transfection and expression in muscle cells
(unpublished data Higgins, Shro¡). However, free
bupivacaine concentrations in mixtures of DNA
and bupivacaine are orders of magnitude below the
threshold concentrations required to cause muscle
degeneration. Furthermore, both intramuscular and
intradermal administration of mixtures of DNA and
bupivacaine generates a high and uniform immune
response when compared to the use of DNA alone
(unpublished data Higgins, Shro¡). The mechanism
of muscle transfection by mixtures of DNA and bu-
pivacaine is not predicted to be related to the process
of bupivacaine pretreatment, due to the temporal
nature of muscle cell degeneration and regeneration,
and the demonstrated lack of muscle damage by the
DNA and bupivacaine mixture.
We have discovered interactions between bupiva-
caine and DNA that may explain the observed in-
crease of in vivo transfection when mixtures of bu-
pivacaine and DNA are used. Aqueous solutions of
bupivacaine form uniform sized complexes, upon di-
rect mixing with DNA. Although these complexes
share some physical and biochemical features with
the synthetic cationic DNA liposomes that have
been shown to transfect cells in vitro, bupivacaine:
DNA complexes are dissimilar in that they are
formed as uniform sized particles of negative zeta
potential, upon both direct mixing in aqueous solu-
tion, as well as when prepared from pre-made bupi-
vacaine vesicles.
2. Materials and methods
2.1. Preparation of complexes
2.1.1. Rapid mixing
Bupivacaine hydrochloride (Sigma, St. Louis, MO,
USA) (2.5% in water, pH 6.4) was added to aqueous
DNA solutions such that the ¢nal bupivacaine
concentration was 0.25%. The experiment was also
performed in 10 mM citrate bu¡er at pH 6.7. The
mixtures were inverted by hand to mix. For density
gradient analysis, complexes were made with
500 ug/ml DNA (charge ratio, +:3 : :5.3:1) that con-
tained 2U105 cpm 33P-labeled DNA. For DNA pro-
tection studies, complexes were made using 500 ug/
ml DNA. For the gold labeling experiment, com-
plexes were made in the presence of gold-labeled
DNA and unlabeled DNA. Gold-labeled plasmid
DNA was mixed with a 10-fold excess of unlabeled
plasmid DNA to a ¢nal DNA concentration of 500
ug/ml.
2.1.2. Slow mixing by dialysis
Bupivacaine was slowly added to DNA by dialysis
of a 0.25% bupivacaine hydrochloride solution across
a 10 kDa membrane over a 3 h period. DNA con-
centrations ranged from 10 ug/ml (+:3 : :264:1) to
800 ug/ml (+:3 : :3.3:1) in the experiments presented
here.
2.1.3. Bupivacaine and bupivacaine:DNA vesicles
prepared from dried ¢lms
An ethanolic solution of bupivacaine hydrochlor-
ide (10 ml) was dried to a thin ¢lm on a rotary
evaporator at 45‡C, and placed under high vacuum
for a minimum of 1 h. The ¢lm was resuspended in a
volume of either water or aqueous DNA solution
(1 mg/ml) for a ¢nal concentration of bupivacaine
of 2.5 mg/ml (+:3 : :2.6:1), and vortexed moderately
for 1 min. Films resuspended in water were subse-
quently treated with aqueous DNA solution for a
¢nal DNA concentration of 1 mg/ml, and a ¢nal
bupivacaine concentration of 2.5 mg/ml. The result-
ing suspensions were processed for transmission and
scanning electron microscopy by drying over EM
grids under vacuum. The structures were visualized
by carbon shadowing (angle of carbon spray = 20‡).
Scanning EM was carried out on gold plated grids to
BBAMEM 77903 21-9-00 Cyaan Magenta Geel Zwart
C.J. Pachuk et al. / Biochimica et Biophysica Acta 1468 (2000) 20^30 21
achieve maximal re£ections. All EM experiments
were carried out at Micron, Wilmington, DE, USA,
on a JEOL TEM and a Phillips TEM.
2.2. Analysis of complexes
2.2.1. Octanol extraction
The mixtures were extracted with an equal volume
of octanol, by vigorous vortex mixing for 1 min and
centrifugation at 12 000 rpm. for 10 min. One hun-
dred microliter of the octanol and water phases were
used to determine bupivacaine concentrations. Bupi-
vacaine concentrations were determined at 260 nm
by reverse phase chromatography, using a C18
HPLC column (Waters, Milford, MA, USA) using
a linear acetonitrile gradient, in 10 mM phosphate, at
pH 6.5.
In order to detect DNA in complexes extracted
into the octanol phase, 500 Wl of the octanol phase
was removed and dried under vacuum. The dried
pellet was resuspended in 0.02 ml of water, and elec-
trophoresed in 1UTris^acetate^EDTA (Sambrook et
al.) on 1% agarose gels. DNA was visualized by
staining with cyber-green (Molecular Probes), a
DNA intercalating £uorescent dye. As control, un-
complexed DNA was also extracted with octanol,
and analyzed as described above.
2.2.2. Density gradient analysis
2.2.2.1. Preparation of 33P plasmid DNA. A plas-
mid transformed, Escherichia coli strain DH10b (Life
Technologies, Grand island, NY, USA) was grown
to stationary phase in 10 ml minimal media contain-
ing limiting PO324 (Neidhardt’s MOPS medium),
5 mCi 33P-orthophosphoric acid (NEN), isoleucine,
leucine and 40 ug/ml kanamycin. Plasmid DNA was
puri¢ed using a hydrophobic interaction matrix (Sig-
ma, St. Louis, MO, USA) followed by chromatogra-
phy on a DEAE-Silica matrix (Qiagen, Valencia, CA,
USA). The eluant was precipitated with 0.7 v/v iso-
propanol. DNA precipitate was collected by centri-
fugation at 12 000 rpm for 10 min, washed with 70%
ethanol and dried under vacuum. The DNA pellet
was dissolved in water. Speci¢c activity of the plas-
mid preparation was calculated by determining the
concentration of DNA, and by scintillation counting
of a fraction of the preparation. Purity of the plas-
mid DNA was ascertained by the ratio of its absor-
bance at 260 and 280 nm, and by electrophoresis on
agarose gels. Gels were soaked in 10% TCA for
10 min, vacuum dried, and exposed to phosphorim-
ager to visualize radioactive 33P material in the prep-
aration.
2.2.2.2. Ficoll density gradients. Discontinuous
gradients were prepared using 3.5 ml of 40% Ficoll
and 6.5 ml of 20% Ficoll. Bupivacaine complexes:
labeled plasmid DNA was mixed with unlabeled
plasmid DNA to achieve a ¢nal speci¢c activity of
2U105 cpm per 500 ug of DNA. Bupivacaine (2.5%
solution) was added to the mixture to a ¢nal concen-
tration of 0.25%, in 1 ml (+:3 : :5.3:1). Lipofectam-
ine (Life Technologies, Grand Island, NY, USA)
complexes: labeled plasmid DNA was mixed with
unlabeled plasmid DNA to achieve a ¢nal speci¢c
activity of 2U105 cpm per 2.5 ug DNA. Lipofect-
amine:DNA complexes were made according to the
manufacturer’s directions and at a +:3 : :5.3:1. Com-
plex volume brought up to 1 ml in water. Replicate
gradients were prepared. Complexed or free DNA
(1 ml) was applied to the gradients. The gradients
were topped o¡ with 1 ml of water, and centrifuged
in an SW41 rotor at 35 000 rpm for 24 h. Following
centrifugation, fractions (0.5 ml) were collected from
the gradient, and the associated radioactivity meas-
ured by scintillation counting.
2.2.2.3. Sucrose density gradients. 3^30% sucrose
density gradients were prepared by repeated freezing
and thawing (four times) of 11 ml of a 15% sucrose
solution. One milliliter of uncomplexed and bupiva-
caine complexed DNA were layered onto the gra-
dient as described for the Ficoll gradients. The gra-
dients were centrifuged in an SW41 rotor at 35 000
rpm for 24 h. 0.5 ml fractions were collected and
analyzed for refractive index determination and scin-
tillation counting.
2.2.2.4. Protection studies with restriction enzyme
SacI. Ten microgram of complexed DNA and un-
complexed DNA were subjected to enzymatic diges-
tion. Replicate samples were digested using the re-
striction enzyme SacI (Promega, Madison, WI,
USA), at 0.25 U/Wg DNA. SacI reactions were per-
formed in 200 Wl, and were incubated at 25‡C. SacI
BBAMEM 77903 21-9-00 Cyaan Magenta Geel Zwart
C.J. Pachuk et al. / Biochimica et Biophysica Acta 1468 (2000) 20^3022
was chosen because it cleaves the plasmid molecule
once, thus linearizing the plasmid. Time course of the
restriction enzyme digestion was generated by
quenching 40 Wl of the reaction mixture with
EDTA (25 mM) at various time intervals. Reaction
products were separated on agarose gels, electropho-
resed in TBE bu¡er, in the presence of ethidium bro-
mide (0.5 Wg/ml), following incubation at 55‡C in the
presence of 10 Wg Proteinase-K (Worthington Bio-
chemical Corp., Freehold, NJ, USA) and 0.5%
SDS. Band intensities were quanti¢ed using a video
gel scanner. Speci¢c intensity of the singularly di-
gested plasmid band was determined by normalizing
the £uorescence intensity of product with the total
intensity in that lane. A time course was plotted to
determine a linear window for the reaction.
2.2.2.5. Protection studies with DNAase. D-
NAase digestions were carried out under conditions
in which only 10% of uncomplexed DNA was di-
gested. Digestions were carried out at 25‡C, in 25
Wl, using 1 Wg complexed or uncomplexed plasmid
DNA, and using 0.05 U of DNAase I (Worthington
Biochemical Corp., Freehold, NJ, USA). The reac-
tions, treated with 0.5% SDS and 10 Wg Proteinase-
K, were electrophoresed on agarose gels as described
previously. The DNA was stained and analyzed as
described above.
2.2.2.6. UV protection. One microgram each of
complexed and uncomplexed DNA were subjected
to 2 min of UV at a distance of 15 cm from the
source. The source was a UV scan box, with a broad
range band width output of 280^320 nm. In control
studies with uncomplexed DNA, nearly 100% cross
linking (UV dimer formation) was achieved in 15
min of UV exposure. DNA in complexes was puri-
¢ed by ethanol precipitation, and extensive washes of
the precipitate with 70% ethanol. UV exposed com-
plexed and uncomplexed DNA were subjected to 1 U
of the bacteriophage T4 endonuclease V (Epicentre,
Madison, WI, USA) digestion. The samples were
treated with 0.5% SDS and 10 Wg of Proteinase-K
prior to agarose gel electrophoresis. Analysis was
carried out as described for the SacI protection ex-
periment.
2.2.2.7. Scanning electron microscopy. All mi-
croscopy was performed by Micron, located in Wil-
mington, DE, USA.
2.2.2.8. Transmission electron microscopy. Bupi-
vacaine:DNA complexes were placed on a collodi-
um/carbon coated 200 mesh copper grid and stained
for 4 min with 0.1% OsO4 and for 30 s with 1%
uranyl acetate. Micrographs were taken with a Phi-
lips 420 electron microscope at 60 kV using a 50 Wm
objective aperture at 51 000U magni¢cation.
2.2.2.9. Gold labeling of DNA. Fifty microgram
of nicked open circular DNA was subjected to a
strand displacement reaction using Klenow (Prome-
ga, Madison, WI, USA), 50 uM dATP, dGTP and
dCTP, 20 uM dUTP and 2 uM biotinylated dUTP
(Boehringer Mannheim, Indianapolis, IN, USA).
The plasmid was puri¢ed from free nucleotides by
two rounds of ethanol precipitation, and two 70%
ethanol washes. The amount of biotin incorporated
into the plasmid was determined by a kinetic ELISA,
by reacting dilutions of the plasmid with streptavi-
din-HRP (Boehringer Mannheim, Indianapolis, IN,
USA). Three molecules of biotin were incorporated
per plasmid molecule. One microgram of biotinyl-
ated plasmid was reacted with 1011 molecules of
gold conjugated streptavidin (Boehringer Mannheim,
Indianapolis, IN, USA). (One microgram of a 5 kbp
plasmid DNA corresponds to 1.25U1014 molecules
and 3.75U1013 conjugated biotin molecules.) The
100-fold excess of conjugated biotin ensures the ab-
sence of free streptavidin-gold. The labeled DNA
was then mixed with unlabeled DNA to achieve a
¢nal DNA concentration of 500 ug/ml. A 2.5% solu-
tion of bupivacaine was added to 0.25% to form
complexes. The mixture was analyzed by transmis-
sion electron microscopy.
3. Results and discussion
3.1. Bupivacaine imparts hydrophobicity to interacting
DNA molecules
The local anesthetic bupivacaine is a cationic am-
phiphile comprised of a protonated cyclic tertiary
amine attached to a hydrophobic dimethyl phenyl
ring via an amide linkage (Fig. 1). The uncharged
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species of bupivacaine partitions readily into non-
polar solvents such as n-octanol. At pH values below
its pKa (pH 8.1), the nitrogen of bupivacaine is pro-
tonated and the bupivacaine molecule is positively
charged. The presence of a positive charge renders
the bupivacaine molecule soluble in water and only
sparingly soluble in n-octanol. We initially observed
that the water solubility of bupivacaine was compro-
mised in the presence of high concentrations of DNA
(s 1 mg/ml) at pH values approaching the pKa of
bupivacaine, suggesting the presence of ionic interac-
tions between the polyanionic DNA and the posi-
tively charged bupivacaine, which result in charge
neutralized complexes.
As amphiphiles, bupivacaine and other local anes-
thetics not only react with cellular membranes, but
also with ion channel proteins [7]. An ionic interac-
tion between bupivacaine and DNA in aqueous so-
lutions at pH6 pKa, would be expected to result in
the charge neutralization of both bupivacaine and
DNA. In addition, the interaction between bupiva-
caine and DNA would be expected to impart a hy-
drophobic nature to the bupivacaine:DNA complex.
Bupivacaine may therefore be expected to confer a
membrane reactive property to complexes with
DNA.
n-Octanol partitioning experiments were used to
partially characterize the nature of the interactions
between bupivacaine and DNA at pH values less
than the pKa of bupivacaine. Both bupivacaine and
DNA are predicted to become more soluble in and
partition into n-octanol, if they form a stable, charge
neutralized complex. Partitioning experiments dem-
onstrate that the partitioning of bupivacaine into
n-octanol is DNA dependent, and that the amount
of bupivacaine extracted into the octanol phase is
proportional to the concentration of DNA in the
mixture (Fig. 1B). An increase in the amount of bu-
pivacaine extracted into octanol corresponds with a
concomitant decrease of bupivacaine in water. One
Fig. 1. (A) Structure of bupivacaine. The molecular structure of bupivacaine is depicted. Note that the cyclic tertiary amine is proto-
nated and positively charged. (B) and (C) Partitioning of DNA:bupivacaine complexes into octanol. (B) Bupivacaine:DNA mixtures
were made using the indicated concentrations of supercoiled plasmid DNA. The mixtures were extracted with octanol. The amount of
bupivacaine in the octanol and water phase was determined and is expressed as the percentage of bupivacaine extracted into either oc-
tanol or water. (C) A bupivacaine:DNA mixture made using plasmid DNA at a concentration of 300 ug/ml (lane 1) or 300 ug/ml
plasmid DNA alone (lane 2) that was octanol extracted. A portion of the octanol phase was dried under vacuum and resuspended in
water. The samples were electrophoresed in 1U Tris^acetate EDTA on a 1% agarose gel. DNA was visualized by staining with cyber-
green. Plasmid DNA that was not octanol extracted (lane 3) was run as a control.
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hundred percent extraction of bupivacaine into octa-
nol from a 0.25% bupivacaine solution was observed
at a DNA concentration of 300 ug/ml (+:3 : :8.8:1).
The polyanionic DNA also partitioned into the
octanol phase when the bupivacaine:DNA mixtures
were octanol extracted. The DNA that was extracted
into the octanol phase was isolated and migrated
with a slower mobility during agarose gel electropho-
resis when compared to uncomplexed DNA (Fig. 1C,
lanes 1 and 3). The decrease in relative mobility is
likely due to changes in both the mass and the charge
of complexed DNA. In the absence of bupivacaine,
DNA did not partition into octanol (Fig. 1C, lane 2).
The results of the octanol partitioning experiment
support the predicted interactions between bupiva-
caine and DNA. DNA is therefore physically associ-
ated with bupivacaine, and some aspects of this in-
teraction must involve the formation of salt bridges,
that result in the charge neutralization of the DNA.
The octanol partitioning data also suggested an
unusual stoichiometry of the interaction. Eight-fold
more molar charge equivalents of bupivacaine were
extracted into the octanol phase than there were
phosphoryl groups present in the DNA. These data
suggest that non-ionic interactions may also play a
role in the formation of complexes. However, ionic
interactions are a prerequisite for complex formation
as evidenced by slower complexation rates in the
presence of competing ions: M2, Na and PO34 ,
or at pH values that preclude electrostatic interac-
tions (data not shown).
3.2. Density gradient analysis of DNA:bupivacaine
complexes
Complexing of bupivacaine and DNA is also pre-
dicted to result in measurable increases in the density
of the complexed DNA. To determine if there were
di¡erences in density between complexed and un-
complexed DNA, and to determine if free DNA
was present in mixtures of bupivacaine and DNA,
the complexes were subjected to analyses by Ficoll
and sucrose density gradient centrifugation. Lipofect-
amine (a DOSPA/DOPE formulation):DNA com-
plexes were used as a control, as these cationic lipid
DNA complexes were shown to generate particles
having a density di¡erent from that of DNA (Fig.
2, top panel). However, it should be noted that lipo-
fectamine:DNA complexes are generated by mixing
preformed cationic liposomes with DNA, and can
not be formed by direct mixing with DNA in aque-
ous solution.
Bupivacaine:DNA complexes made by direct mix-
ing, and lipofectamine:DNA complexes made in the
presence of 33P-labeled supercoiled plasmid DNA
were characterized by Ficoll density gradient rate
centrifugation. In experiments with uncomplexed
33P-DNA, fractions 1, 2 and 3 contained the uncom-
plexed labeled DNA (Fig. 2, top panel). In experi-
ments with bupivacaine complexed DNA, the major-
ity of labeled DNA was found in fractions 4, 5, 6 and
7, indicating that these complexes sediment with a
Fig. 2. Density gradient pro¢les of complexed and uncomplexed
DNA. (A) Ficoll gradient analysis. Uncomplexed radiolabeled
DNA and bupivacaine and lipofectamine complexed DNA
made with radiolabeled DNA were centrifuged through a 20^
40% Ficoll gradient. 0.5 ml fractions were collected and the as-
sociated radioactivity measured by scintillation counting. Rela-
tive migrations of the uncomplexed and complexed DNA are
indicated. (B) Sucrose density gradient analysis. Uncomplexed
radiolabeled DNA and radiolabeled DNA complexed with bu-
pivacaine were centrifuged through a 3^30% sucrose gradient.
0.5 ml fractions were collected, and the associated radioactivity
measured by scintillation counting. The relative migration of
uncomplexed and complexed DNA is indicated.
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higher density than supercoiled DNA alone. Less
than 3% of the total DNA was found in fractions
1^3, where uncomplexed supercoiled DNA migrates
in the gradient. Lipofectamine complexed DNA also
sedimented at densities higher than DNA alone, and
was more dense than the bupivacaine:DNA com-
plexes. Furthermore, the lipofectamine:DNA com-
plexes were broadly distributed throughout the gra-
dient suggesting that the complexes were more
heterogeneous than the bupivacaine:DNA com-
plexes. In addition, while lipofectamine:DNA com-
plexes (+:3 : :5.3:1) have a positive net surface
charge of +20, the bupivacaine:DNA complexes
(+:3 : :5.3:1) have a negative zeta potential of 352
(data not shown). The bupivacaine:DNA complexes
thus appear to be more similar to the cationic deter-
gent^DNA complexes described by Blessing [8].
Although the primary interactions with DNA are
predicted to be similar for both bupivacaine and
lipofectamine, and are mediated through their re-
spective cationic headgroups, the secondary and ter-
tiary hydrophobic interactions are likely to be di¡er-
Fig. 3. Scanning and transmission electron micrographs of bupivacaine:DNA complexes. (A) Scanning electron micrographs are pre-
sented of DNA:bupivacaine complexes photographed at 50 000U (top), bupivacaine alone, photographed at 25 000U (middle) and
DNA alone, photographed at 25 000U (bottom). (B) Transmission electron micrographs of DNA:bupivacaine complexes stained with
osmiumtetroxide and uranyl acetate are shown. (Scale: 1.5 cm = 100 nm.)
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ent. Lipofectamine has two long aliphatic chains
while bupivacaine has a dimethyl phenyl group.
These di¡erences are re£ected in the solubility di¡er-
ences of the two molecules in both polar and non-
polar solvents. It is therefore tempting to speculate
that density and charge di¡erences between bupiva-
caine and lipofectamine complexes are the result of
their secondary and tertiary interactions. In addition,
complexes made with lipofectamine and other similar
cationic lipids are made by mixing DNA with preas-
sembled liposomes. Liposome formation is primarily
mediated through hydrophobic interactions, and ad-
dition of DNA acts to e¡ect the reordering of these
pre-existing structures. Direct mixing of DNA and
bupivacaine, on the other hand, allows electrostatic
and hydrophobic interactions to occur simultane-
ously.
Bupivacaine:DNA complexes were also character-
ized by sucrose density gradient rate centrifugation.
Sucrose density gradients were chosen to improve the
resolution of bupivacaine:DNA complexes. Uncom-
plexed DNA was found in fractions 12, 13 and 14
(15^18% sucrose) while the bupivacaine:DNA com-
plexes were found in fractions 16, 17, 18 and 19 (at
22^29% sucrose) (Fig. 2, bottom panel). Symmetry of
the bupivacaine:DNA complex peak suggests the ab-
sence of detectable amounts of uncomplexed DNA
(less than 1%) suggesting that all of the DNA is
complexed with bupivacaine. The narrow symmetri-
cal Gaussian distribution is also consistent with the
presence of complexes that are homogeneous in den-
sity.
3.3. Electron microscopic characterization of
complexes
To further characterize the complexes of DNA and
bupivacaine derived from direct mixing of aqueous
solutions of these molecules, they were analyzed by
both scanning and transmission electron microscopy.
Scanning electron microscopy reveals the presence of
50^70 nm particles arranged in clusters (Fig. 3A,
top). The uniform size of these particles is consistent
with the homogeneous nature of the complexes re-
vealed by density gradient centrifugation. These par-
ticles are not seen in the bupivacaine and uncom-
plexed DNA control (Fig. 3A, middle and bottom);
only particles with the size of supercoiled DNA can
be seen in the DNA control. The typical ‘beads on a
string’ structures that have been reported for cationic
liposome:DNA complexes [9] can also be observed in
transmission electron micrographs of these prepara-
tions (Fig. 3B).
In order to con¢rm the presence of DNA in these
structures we have employed bupivacaine:DNA
complexes made with gold-labeled DNA. Complexes
of gold-labeled DNA were analyzed by transmission
electron microscopy. Results in Fig. 4 show that the
gold label is associated with the complexes. These
70 nm labeled particles appear to be contained within
higher order vesicle-like structures.
3.4. Complexed DNA is protected from nucleases and
ultraviolet light
To determine if any of the DNA associated with
the particle is in the interior of the particle, DNA
protection experiments were performed. The extent
to which complexed DNA is susceptible to enzymatic
digestion has routinely been used as a measure of
complexation. Protection of complexed DNA from
nucleases (DNAase I or restriction endonucleases)
has been previously cited as a measure of complex-
ation [10]. The DNA in bupivacaine:DNA com-
plexes is also protected from nucleases. Over 10-
fold more protection has been observed with bupiva-
caine complexed DNA when compared with the di-
Fig. 4. Complexes made with gold-stained DNA. Transmission
electron micrographs of DNA:bupivacaine complexes made
with gold-stained DNA.
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gestion rate of uncomplexed DNA. The basis of
DNA protection in all such studies has been attrib-
uted to entrapment of DNA into liposome-like
vesicles. The premise of these experiments, however,
is questionable. Cationic lipid or bupivacaine com-
plexes of DNA may not be a nuclease substrate, the
true substrate being DNA with a divalent cation co-
ordinated to the oxygen on the phosphoryl group.
Therefore, the protection results are only indicative
of an altered substrate, and not necessarily of un-
availability due to entrapment. In addition, the un-
reacted molecules of the cationic reagent may be
non-competitive inhibitors of the enzyme.
We have devised a novel approach to determine if
DNA is present in the interior of bupivacaine:DNA
complexes. The approach is to determine the level of
protection from ultraviolet light. Ultraviolet light in-
duces thymidine dimer formation of neighboring thy-
midines in DNA. If DNA is free or is associated on
the outside or is in the outer lea£et of the vesicle-like
structures of the bupivacaine:DNA complexes, adja-
cent thymidines are expected to form dimers upon
exposure to ultraviolet light. Since bupivacaine ab-
sorbs UV (Vmax = 259 nm), it is expected to protect
DNA from UV-induced dimer formation only when
the DNA is in the interior of the complexes. Follow-
ing exposure of the complexes to UV light, DNA was
puri¢ed from bupivacaine and incubated with the
repair enzyme, T4 endonuclease V. This enzyme
cleaves the 5P glycosyl bond and the phosphodiester
linkage located 3P to the thymidine dimer, resulting
in removal of the thymidine dimer. Control DNA
exposed to UV light and incubated with the repair
enzyme was analyzed by agarose gel electrophoresis.
As anticipated, the DNA was degraded by the repair
endonuclease. Note the absence of supercoiled DNA
Fig. 5. UV protection analysis. DNA (lanes 1, 2 and 3), or
DNA complexed with bupivacaine (lanes 4, 5 and 6) were ex-
posed to UV alone (lanes 2 and 5) or exposed to UV and then
incubated with T4 endonuclease V (lanes 3 and 6) as described
in Section 2. DNA was then subjected to agarose gel electro-
phoresis. Control DNA (lane 1) or control complexed DNA
(lane 4) was not exposed to UV or incubated with T4 endonu-
clease V. The positions of supercoiled (sc), linear (l) or open
circular (oc) plasmid DNA forms are indicated.
Fig. 6. Scanning electron micrographs of bupivacaine and bupivacaine:DNA vesicles prepared from dry ¢lms. (A) Bupivacaine vesicles
formed by hydration of a bupivacaine ¢lm with water. (B) Bupivacaine:DNA vesicles formed by the addition of aqueous DNA to bu-
pivacaine vesicles prepared as described for A.
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in Fig. 5, lane 3. However, DNA isolated from com-
plexes that were exposed to UV light and then sub-
jected to enzymatic digestion were partially protected
(Fig. 5, compare lane 6 with lane 3). Protection of
complexed DNA indicates the presence of DNA in
the interior of the vesicle-like structures. The pres-
ence of some unprotected DNA in the complexes,
the negative zeta potential of the particles and the
absence of free DNA, suggest that some DNA is
associated on the particle’s exterior surface.
3.5. Rehydration of dried ¢lms
Although the addition of aqueous solutions of bu-
pivacaine to DNA results in complex formation, we
have also demonstrated that bupivacaine alone can
form vesicular liposome-like structures when hy-
drated from dried ¢lms. When observed by scanning
electron microscopy, these structures (Fig. 6A) ap-
pear to be similar to those vesicles prepared from
¢lms of cationic lipid [11]. These vesicles assume col-
lapsed and condensed structures when mixed with
DNA (Fig. 6B). The results indicate that preformed
bupivacaine vesicles can also interact with DNA,
similar to complexes formed with other cationic lip-
ids.
3.6. Controlled assembly
In order to control the rate of assembly and the
size of the resultant particles, the steps of complex-
ation must be ordered. This can potentially be
achieved by slowing the reaction rate. This is ex-
pected to allow stabilization of the primary reactions
prior to the development of competing secondary
and tertiary reactions that consume one or both of
the reactants unproductively. We have controlled the
rate of bupivacaine and DNA interaction by slowing
Fig. 7. Generation of unimolecular and multimolecular complexes by controlled assembly. (A) Complexes formed by slow mixing are
unimolecular at low DNA concentrations. DNA alone or DNA complexed with bupivacaine was subjected to agarose gel electropho-
resis. Lane 1, 1 kbp ladder (Gibco-BRL); lane 2, X174RF DNA; lane 3, X174RF DNA complexed with bupivacaine; lane 4, plasmid
A DNA; lane 5, plasmid A DNA complexed with bupivacaine; and lane 6, X174RF DNA and plasmid A DNA complexed with bu-
pivacaine. (B) Scanning electron micrograph of complexes made by slow mixing and at DNA concentrations of 10 ug/ml (top) and
transmission electron micrograph of complexes made by slow mixing and at DNA concentrations of 10 ug/ml or 800 ug/ml.
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the rate of mixing. Slow mixing was achieved by
dialyzing bupivacaine across a 10 kDa membrane,
into a solution of DNA. At low DNA concentrations
(10^100 ug/ml) (+:3 : :264:1)^(+:3 : :26.4:1), unimo-
lecular complexes are made that contain a singular
DNA molecule (Fig. 6). At low DNA concentrations
(100 ug/ml), complexes made with either supercoiled
ox174 DNA (a 2 kbp DNA) or a supercoiled 8 kbp
plasmid DNA (plasmid A), demonstrate distinctly
di¡erent gel shifted bands with respect to each other
(Fig. 7A, compare lanes 3 and 5). Multimolecular
complexes (containing more than one DNA mole-
cule) made with a mixture of the two DNA mole-
cules are predicted to result in gel shifts that are
intermediate to those exhibited in lanes 3 and 5.
The absence of intermediate gel shifts (Fig. 7A,
lane 6) argues against the formation of multimolec-
ular complexes at low DNA concentrations and sug-
gests the formation of unimolecular complexes.
However, at higher DNA concentrations the inter-
mediates of unimolecular complexes undergo tertiary
interactions, resulting in larger complexes. Increasing
amounts of DNA in the reaction mixture result in
the formation of aggregates that are gel shifted to
higher positions on the gel (data not shown). Elec-
tron micrographs are consistent with this result (Fig.
7B). At all DNA concentrations tested (10 Wg^2 mg/
ml), all of the DNA was found to be complexed with
bupivacaine. These results suggest that DNA con-
tributes to and is a participant in the secondary in-
teractions. However, the secondary and tertiary in-
teractions and the nature of the complexes are
expected to vary, and are expected to be dependent
upon both the DNA and bupivacaine concentrations.
4. Summary
Bupivacaine, a cationic amphiphile, at pH6pKa,
interacts with DNA to form stable complexes. These
complexes di¡er from those described for other cat-
ionic lipid:DNA complexes in that they are homoge-
neous in size and have a negative zeta potential. Fur-
thermore, unlike other cationic lipid mixtures of
DNA, these complexes can be made by directly mix-
ing aqueous solutions. In addition, intramuscular im-
munization with bupivacaine:DNA complexes re-
sults in immune responses that are greater than
those incurred with ‘naked DNA’. In general, com-
plexes made with other cationic lipids do not result
in these responses. In one report, however, the use of
dehydration^rehydration vesicles (DRVs) comprised
of DNA and cationic lipids has been shown to en-
hance immune responses [12]. DRV particles are
smaller and more uniform in size than the previously
described cationic lipid:DNA complexes. The smaller
size of the DRV particles may be a critical parameter
for their ability to generate enhanced immune re-
sponses. It will be interesting to determine which
biophysical parameters of bupivacaine:DNA com-
plexes are critical for in vivo transfection and subse-
quent generation of immune responses.
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